Eli Lilly Appoints Company Insider Lucas Montarce as New CFO Amid Weight Loss Drug Boom

Benzinga

Eli Lilly has appointed Lucas Montarce as its new Chief Financial Officer, following the departure of former CFO Anat Ashkenazi, who left to join Alphabet. Montarce has been a company insider since 2001 and has held several leadership roles within Lilly. His appointment comes as the pharmaceutical giant invests billions to boost manufacturing capacity for its diabetes and weight loss drugs, Mounjaro and Zepbound. These drugs are expected to drive a weight loss drug market that could reach $150 billion within the next decade.

Transcript

00:00It's Benzinga, and here's what's on the block.

00:02Eli Lilly has appointed Lucas Montars as its new chief financial officer following the

00:07departure of former CFO Anat Ashkenazi, who left to join Alphabet.

00:11Montars had been a company insider since 2001 and has held several leadership roles within

00:16Lilly.

00:17His appointment comes as the pharmaceutical giant invests billions to boost manufacturing

00:21capacity for its diabetes and weight loss drugs, Bonjaro and Zepound.

00:26These drugs are expected to drive a weight loss drug market that could reach $150 billion

00:30within the next decade.

00:31For all things money, visit Benzinga.com.

Category

Transcript

Comments

Recommended